Safely Transition Patients Taking the New Nebulized Med Yupelri at Home

April 2019

You'll see Yupelri (yoo-PEL-ree, revefenacin), the first ONCE-daily nebulized long-acting muscarinic antagonist (LAMA) for COPD.

It will have an edge over TWICE-daily Lonhala Magnair (glycopyrrolate)...the only other nebulized LAMA.

Yupelri is given via a standard nebulizer. Lonhala requires its own Magnair nebulizer...which can't be used to nebulize other meds.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote